ArticleBMC biotechnology2015
Evaluating whole transcriptome amplification for gene profiling experiments using RNA-Seq.
Article in BMC biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease.Nature communications · 2023Article
- Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease.bioRxiv : the preprint server for biology · 2023Article
- A pan-cancer analysis of pituitary tumor-transforming 3, pseudogene.American journal of translational research · 2023Article
- Multi-gene technical assessment of qPCR and NanoString n-Counter analysis platforms in cynomolgus monkey cardiac allograft recipients.Cellular immunology · 2020Article
- The haustorial transcriptome of the cucurbit pathogen Podosphaera xanthii reveals new insights into the biotrophy and pathogenesis of powdery mildew fungi.BMC genomics · 2019Article
- Evaluation of ultra-low input RNA sequencing for the study of human T cell transcriptome.Scientific reports · 2019Article
- Systematic analysis of TruSeq, SMARTer and SMARTer Ultra-Low RNA-seq kits for standard, low and ultra-low quantity samples.Scientific reports · 2019Article
- Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk.Scientific reports · 2019Article
- Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease.Nature neuroscience · 2018Article
- A comparative analysis of library prep approaches for sequencing low input translatome samples.BMC genomics · 2018Article
- Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.Cancer immunology research · 2018Article
- High-resolution transcriptional dissection of in vivo Atoh1-mediated hair cell conversion in mature cochleae identifies Isl1 as a co-reprogramming factor.PLoS genetics · 2018Article
- Genome sequence and population declines in the critically endangered greater bamboo lemur (Prolemur simus) and implications for conservation.BMC genomics · 2018Article
- Trehalose Contributes to Gamma-Linolenic Acid Accumulation inFrontiers in microbiology · 2018Article
- Robust transcriptional signatures for low-input RNA samples based on relative expression orderings.BMC genomics · 2017Article
- A comprehensive assessment of RNA-seq protocols for degraded and low-quantity samples.BMC genomics · 2017Article
- Age and Alzheimer's disease gene expression profiles reversed by the glutamate modulator riluzole.Molecular psychiatry · 2017Article
- Gene Expression Profiling in the Hibernating Primate, Cheirogaleus Medius.Genome biology and evolution · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRNA-Seq has enabled high-throughput gene expression profiling to provide insight into the functional link between genotype and phenotype. Low quantities of starting RNA can be a severe hindrance for studies that aim to utilize RNA-Seq. To mitigate this bottleneck, whole transcriptome amplification (WTA) technologies have been developed to generate sufficient sequencing targets from minute amounts of RNA. Successful WTA requires accurate replication of transcript abundance without the loss or distortion of specific mRNAs. Here, we test the efficacy of NuGEN's Ovation RNA-Seq V2 system, which uses linear isothermal amplification with a unique chimeric primer for amplification, using white adipose tissue from standard laboratory rats (Rattus norvegicus). Our goal was to investigate potential biological artifacts introduced through WTA approaches by establishing comparisons between matched raw and amplified RNA libraries derived from biological replicates.
resultsWe found that 93% of expressed genes were identical between all unamplified versus matched amplified comparisons, also finding that gene density is similar across all comparisons. Our sequencing experiment and downstream bioinformatic analyses using the Tuxedo analysis pipeline resulted in the assembly of 25,543 high-quality transcripts. Libraries constructed from raw RNA and WTA samples averaged 15,298 and 15,253 expressed genes, respectively. Although significant differentially expressed genes (P < 0.05) were identified in all matched samples, each of these represents less than 0.15% of all shared genes for each comparison.
conclusionsTranscriptome amplification is efficient at maintaining relative transcript frequencies with no significant bias when using this NuGEN linear isothermal amplification kit under ideal laboratory conditions as presented in this study. This methodology has broad applications, from clinical and diagnostic, to field-based studies when sample acquisition, or sample preservation, methods prove challenging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.